SCHEMBL29699353

SCHEMBL29699353

Clc1ccc(-c2ccc(Sc3c[nH]nn3)c(Cl)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.37
NOTUM Q6P988 1/20 0.36
LMNA P02545 2/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
ITGB2 P05107 1/20 0.34
ICAM1 P05362 1/20 0.34
ITGAL P20701 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 2/20 0.33
ATM Q13315 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
RPA1 P27694 1/20 0.33
ALOX5 P09917 1/20 0.32
AKT2 P31751 3/20 0.31
RHEB Q15382 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23457569 1.00 AHR (0.37) AHRNOTUMLMNAGAAMAPT
SCHEMBL23457507 0.81 HAO1 (0.43) NOTUMLMNAMAPTKMT2AMEN1
SCHEMBL29699607 0.81 AHR (0.42) AHRNOTUMLMNAMAPTKMT2A
SCHEMBL23458008 0.81 AHR (0.42) AHRNOTUMLMNAMAPTKMT2A
SCHEMBL23457570 0.75 ALDH1A1 (0.38) AHRLMNAKMT2AMEN1ALDH1A1
SCHEMBL23457559 0.72 MARS1 (0.42) AHRLMNAMAPTALDH1A1ATM
SCHEMBL29699370 0.70 HAO1 (0.53) NOTUMLMNAMAPTKMT2AMEN1
SCHEMBL23457543 0.70 RPA1 (0.42) NOTUMALDH1A1RPA1AKT2AKT1
SCHEMBL23457595 0.69 LMNA (0.40) LMNAMAPTALDH1A1ATMSMN1; SMN2
SCHEMBL29699478 0.69 LMNA (0.40) LMNAMAPTALDH1A1ATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT AHR 3115/4885NOTUM 643/4885LMNA 2434/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT AHR 2840/4885NOTUM 602/4885LMNA 2638/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT AHR 3115/4885NOTUM 643/4885LMNA 2434/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT AHR 3115/4885NOTUM 643/4885LMNA 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.